Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 19 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

16%

3 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

14 recruiting

Enrollment Performance

Analytics

Phase 4
3(42.9%)
N/A
3(42.9%)
Early Phase 1
1(14.3%)
7Total
Phase 4(3)
N/A(3)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials
NCT07111273Recruiting

DYNAMIC-UC: Early qFIT and Calprotectin Change Predicting Relapse in Biologic-Naive Ulcerative Colitis

Role: collaborator

NCT07111572Recruiting

Fecal biOmarker Response Evaluation for Super-Early Efficacy in Ulcerative Colitis

Role: collaborator

NCT07413068Recruiting

Treatment Outcomes and Complications of Three Therapeutic Approaches for Concomitant Choledocholithiasis and Cholecystolithiasis

Role: collaborator

NCT07495111Not ApplicableRecruiting

Prophylactic PS Placement to Prevent Pancreatitis After Endoscopic Transpapillary GPC for Cholelithiasis With Concomitant Choledocholithiasis

Role: collaborator

NCT06284642Phase 4Recruiting

Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK)

Role: collaborator

NCT07179159Not ApplicableRecruiting

Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial

Role: collaborator

NCT07335406Recruiting

Registry for the Management of Helicobacter Pylori Infection in Shandong Province

Role: collaborator

NCT07402135Not ApplicableNot Yet Recruiting

Fecal Noninvasive Biomarkers Oriented Control Versus Usual Care Strategy in Ulcerative Colitis

Role: collaborator

NCT07379281Recruiting

Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology

Role: collaborator

NCT07379268Recruiting

Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.

Role: collaborator

NCT07379255Recruiting

Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology.

Role: collaborator

NCT07285096Recruiting

P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication

Role: collaborator

NCT07167511Completed

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

Role: collaborator

NCT06285734Recruiting

Clinical Characteristics of Small Intestinal Bacterial Overgrowth in Individuals with Abdominal Distention

Role: collaborator

NCT06723197Phase 4Recruiting

Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication

Role: collaborator

NCT06592118Completed

Clinical and Surgical Outcomes of Thyroid Carcinoma in Children and Adolescents

Role: lead

NCT06557018Phase 4Recruiting

Efficacy and Safety of Liposomal Bupivacaine Using Periarticular Injection in Total Knee Arthroplasty

Role: lead

NCT06437912Early Phase 1Completed

Effectiveness of Botulinum Toxin A in Preventing Scar Formation and Initial Exploration of "Optimal Concentration"

Role: lead

NCT06437873Completed

Long-term Survival Outcomes of Total Thyroidectomy and Radioactive Iodine Therapy in Unilateral T3/T4 FTC

Role: lead

All 19 trials loaded